[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Umoja Biopharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100649540","phase-1-a-phase-12-study-of-ub-vv400-with-rapamycin-in-relapsedrefractory-b-cell-malignancies-100649540",false,"NCT07735533","A Phase 1\u002F2 Study of UB-VV400 With Rapamycin in Relapsed\u002FRefractory B-cell Malignancies","A Phase 1\u002F2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies","Inclusion Criteria:\n\n1. 18 years or older\n2. Provides voluntary written informed consent\n3. Relapsed or refractory large B-cell lymphoma (LBCL)\n4. Measurable disease according to Lugano 2014 criteria\n5. Confirmed CD22 expression\n6. No serious concomitant diseases or active\u002Funcontrolled infections\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n8. Adequate organ function\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding\n2. Current isolated central nervous system (CNS) involvement\n3. Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (except tumor-infiltrating lymphocytes, CAR-NK cells, T-cell receptor \\[TCR\\] fusion constructs, TCR T cells, and CAR T cells)\n4. History of or active human immunodeficiency virus (HIV)\n5. Active or chronic hepatitis B, or active hepatitis C\n6. Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease\n7. Ongoing CNS disease that would preclude neurologic assessment\n8. Uncontrolled angina or other acute heart disease\n9. Currently receiving treatment in another interventional clinical trial.","ALL","18 Years",{"count":19,"type":20},274,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study is a Phase 1\u002F2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed\u002Frefractory B-cell malignancies, including large B-cell lymphoma (LBCL).",[27,28,29,30,31,32,33],"Lymphoma, B Cell","Lymphoma Non-Hodgkin","High Grade B Cell Lymphoma","Richter Transformation Lymphoma","Grade 3b Follicular Lymphoma","Primary Mediastinal B Cell Lymphoma","Diffuse Large B Cell Lymphoma (DLBCL)",[35,36,37],"CAR T","chimeric antigen receptor","CD22","NOT_YET_RECRUITING","2026-08-13",{"date":41,"type":42},"2026-08-17","ACTUAL",{"date":44,"type":20},"2026-08",{"date":46,"type":20},"2031-08",{"name":48,"class":49},"Umoja Biopharma","INDUSTRY",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100649498","phase-1-a-phase-1-study-of-ub-vv500-with-rapamycin-in-relapsedrefractory-multiple-myeloma-100649498","NCT07735546","A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed\u002FRefractory Multiple Myeloma","A Phase 1, Open-label, Multicenter Study of UB-VV500 With Rapamycin in Relapsed or Refractory Multiple Myeloma","Inclusion Criteria:\n\n1. 18 years or older\n2. Provides voluntary written informed consent\n3. Relapsed or refractory multiple myeloma (MM) following treatment with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody\n4. Measurable disease following completion of most recent anticancer therapy\n5. No serious concomitant diseases or active\u002Funcontrolled infections\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Adequate organ function\n\nExclusion Criteria:\n\n1. Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis\n2. Solitary plasmacytomas without evidence of systemic disease\n3. Women who are pregnant or breastfeeding\n4. Current isolated central nervous system (CNS) involvement\n5. Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (except tumor-infiltrating lymphocytes, CAR-NK cells, T-cell receptor \\[TCR\\] fusion constructs, TCR T cells, and CAR T cells)\n6. History of or active human immunodeficiency virus (HIV)\n7. Active or chronic hepatitis B, or active hepatitis C\n8. Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease\n9. Ongoing CNS disease that would preclude neurologic assessment\n10. Uncontrolled angina or other acute heart disease\n11. Currently receiving treatment in another interventional clinical trial.",{"count":58,"type":20},100,[23],"This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed\u002Frefractory multiple myeloma.",[62,63],"Multiple Myeloma in Relapse","Multiple Myeloma (MM)",[35,36,65,66],"BCMA","GPRC5D",{"date":41,"type":42},{"date":69,"type":20},"2026-10-01",{"date":71,"type":20},"2029-12-31",{"name":48,"class":49},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100556684","phase-1-a-phase-1-study-of-ub-vv111-with-and-without-rapamycin-in-relapsedrefractory-cd19-b-cell-malignancies-100556684","NCT06528301","A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed\u002FRefractory CD19+ B-cell Malignancies","A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed\u002FRefractory (R\u002FR) CD19+ B-cell Malignancies","Inclusion Criteria:\n\n1. 18 years or older\n2. Provides voluntary written informed consent\n3. Relapsed or refractory large B-cell lymphoma (LBCL) or chronic lymphocytic leukemia (CLL)\n4. Measurable disease according to Lugano 2014 criteria (LBCL) or iwCLL 2018 (CLL).\n5. No serious concomitant diseases or active\u002Funcontrolled infections\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Adequate organ function\n8. Patients who have previously received CD19-directed therapy must have biopsy confirming CD19 expression following completion of prior CD19-directed therapy.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding\n2. Current isolated central nervous system (CNS) involvement\n3. Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (exceptions include tumor-infiltrating lymphocytes and CAR T cells)\n4. History of or active human immunodeficiency virus (HIV)\n5. Active hepatitis B or C\n6. Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease\n7. Ongoing CNS disease that would preclude neurologic assessment\n8. Uncontrolled angina or other acute heart disease\n9. Currently receiving treatment in another interventional clinical trial.",{"count":81,"type":20},106,[23],"This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed\u002Frefractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).",[85,86,87,88],"Lymphoma, B-Cell","Lymphoma, Non-Hodgkin (NHL)","Lymphoma, Large B-Cell, Diffuse (DLBCL)","Chronic Lymphocytic Leukemia (CLL)",[35,90,36],"CD19","RECRUITING",{"date":41,"type":42},{"date":94,"type":42},"2025-03-10",{"date":96,"type":20},"2029-03",{"name":48,"class":49},8,""]